|1.||García Fadul, Christian: 1 article (01/2015)|
|2.||Laporta, Rosalia: 1 article (01/2015)|
|3.||Portero, Francisca: 1 article (01/2015)|
|4.||Lopez Garcia-Gallo, Cristina: 1 article (01/2015)|
|5.||Millan, Isabel: 1 article (01/2015)|
|6.||Ussetti, Piedad: 1 article (01/2015)|
|7.||Twist, Clare J: 1 article (01/2013)|
|8.||Castillo, Ricardo O: 1 article (01/2013)|
|9.||Libertucci, Daniela: 1 article (01/2011)|
|10.||Hung, Yu-Shin: 1 article (01/2011)|
11/01/2005 - "A significant reduction in CMV infection was noted in the CytoGam Group compared with the Placebo Group (15.4% [2/13] vs 60% [6/10], p = .039). "
10/01/2009 - "In multivariable models, patients who did not receive CMVIG as part of their prophylaxis were 3 times more likely to develop CMV infection (hazard ratio, 3.4; 95% confidence interval, 1.2-9.5) independent of CMV serostatus. "
01/01/2008 - "CMVIG had no impact on CMV-infections and clinically relevant rejections. "
01/01/2001 - "Antibody-dependent, effector cell-mediated functions may underlie the ability of CytoGam to prevent or modulate CMV infection in vivo."
01/01/2001 - "The combination of CytoGam and either of the effector cell types markedly inhibited established CMV infection in vitro. "
07/01/1988 - "The improved survival of patients in this trial may be due to a small number of patients (23%) who developed significant neutropenia during ganciclovir therapy, to the concurrent use of CMV immune globulin in three of the survivors, or to other variables affecting a positive outcome. "
07/01/2003 - "Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients."
10/01/2009 - "Data from adult centers suggests that CMV hyperimmune globulin (CMVIG) and ganciclovir together are superior in preventing CMV viremia than ganciclovir alone. "
01/01/2015 - "None of the 18 donor seropositive/recipient seronegative patients who were switched from valganciclovir to CMVIg for persistent leukopenia developed CMV viremia during treatment. "
01/01/2013 - "EBV viremia developed 8 weeks posttransplantation, and despite treatment with cytogam and valganciclovir the patient developed a polymorphic, CD20+, EBV+ PTLD with peripheral lymphadenopathy. "
01/01/2001 - "A combination of CytoGam plus ganciclovir in OLT recipients has resulted in reductions in CMV hepatitis and infection, and CMV disease and viremia, plus a trend in improved 1- and 2-year survival rates."
11/15/1993 - "Using a Cox proportional hazards model, CMVIG was shown to reduce severe CMV-associated disease (multi-organ CMV disease, CMV pneumonia, or invasive fungal disease associated with CMV infection) from 26% to 12% (relative risk, 0.39; 95% CI, 0.17 to 0.89). "
11/01/1990 - "In the second patient, who required augmented immunosuppression because of recurrent lung rejection early postoperatively, fulminating CMV pneumonitis developed, which was ultimately controlled with ganciclovir and high-dose CMV immune globulin. "
11/01/1990 - "CMV immune globulin prophylaxis may be effective in preventing clinical CMV disease in patients receiving a CMV-mismatched graft, and severe CMV pneumonitis may be effectively treated by a combination of ganciclovir and high-dose CMV immune globulin therapy."
01/01/2011 - "We evaluated the effect of CMV-Immunoglobulins (CMV-IG) (Cytotect Biotest) on CMV pneumonia diagnosed in 303 follow-up transbronchial biopsies (TBB) of lung transplant recipients. "
01/01/2011 - "Effect of CMV-immunoglobulins (cytotect biotest) prophylaxis on CMV pneumonia after lung transplantation."
|4.||Intravenous Immunoglobulins (IVIG)
|5.||cytomegalovirus-specific hyperimmune globulin
|7.||hepatitis B hyperimmune globulin
|8.||varicella-zoster immune globulin (VZIG)
|2.||Transplantation (Transplant Recipients)
|3.||Homologous Transplantation (Allograft)